Treatment of subacute sclerosing panencephalitis with interferon-alpha, ribavirin, and inosiplex

Tom Solomon1, C Anthony Hart, Sobhan Vinjamuri

  • 1Department of Neurological Science, University of Liverpool, United Kingdom. tsolomon@liv.ac.uk

Journal of Child Neurology
|December 31, 2002
PubMed

Insights

Subacute sclerosing panencephalitis (SSPE), a fatal measles complication, showed marked improvement with a novel combination therapy including interferon-alpha, ribavirin, and inosiplex. Though temporary, this treatment highlights potential therapeutic avenues for SSPE.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Virology

Background:

  • Subacute sclerosing panencephalitis (SSPE) is a rare, progressive, and fatal neurological complication of measles virus infection.
  • Currently, no established effective treatment exists for SSPE, leading to a universally fatal outcome.

Observation:

  • A patient with severe SSPE, presenting with significant neurological deficits including ataxia, hemiparesis, and myoclonus, was treated with a novel regimen.
  • The treatment involved intraventricular interferon-alpha, intravenous ribavirin, and oral inosiplex.

Findings:

  • The patient demonstrated marked neurological and functional improvement during the initial 10 weeks of combination therapy.
  • Despite initial success and continued improvement on oral therapy, the patient experienced sudden deterioration and expired after 10 months.

Implications:

  • This case suggests that combination therapy, particularly with intraventricular interferon-alpha, may offer temporary benefits in managing severe SSPE.
  • Further research and clinical trials are warranted to explore the long-term efficacy and optimal strategies for combination therapy in SSPE.